Chronic Lyme disease
Most patients who are labeled as having chronic Lyme disease will fall into categories 1 and 2. Patients in category 1 are diagnosed with chronic Lyme disease based on unexplained symptoms without objective or valid laboratory evidence of infection Borrelia burgdorferi. Patients in category 2 have other recognized diseases and have been misdiagnosed with Lyme disease. The distribution of patients who fall into these categories can be estimated by the difficulty in accruing patients into the placebo-controlled studies of antibiotic treatment in patients with post-Lyme disease syndrome (Category 4), where only 1% to 10% of the screened individuals were eligible [2] [3] [4] .
There have been numerous studies addressing the issue of overdiagnosis of Lyme disease (Table 1) , and although these studies represent the experience of referral centers, they are informative regarding the range of patients seeking further evaluation for suspected Lyme disease. In general, only about one quarter to one third of the patients evaluated were thought to have Lyme disease; in comparison, between 50% to 60% of the patients had no present or past evidence of Lyme disease. A large portion of patients presented with fatigue, myalgias, arthralgias, sleep disturbances, memory complaints, and/or depression, and many fulfilled criteria for chronic fatigue syndrome or fibromyalgia [5] [6] [7] [8] [9] [10] . Common and related problems contributing to the overdiagnosis of Lyme disease included the use of serologic testing in clinical situations in which the pretest probability of Lyme disease was low, misinterpretation of test results, and use of nonvalidated methods and criteria for interpretation of laboratory results.
Post-Lyme disease syndrome
Many studies have shown that Lyme disease is treated successfully with antibiotics in most cases, and patients who have objective evidence of treatment failure are rare with currently recommended regimens [11] [12] [13] [14] . Patients who have late manifestations can have a slower response to therapy, sometimes taking weeks or months to recover [15] [16] [17] [18] [19] [20] [21] [22] [23] . Some patients may have incomplete resolution because of irreversible damage, as can occur in facial nerve palsy with residual facial weakness. A few patients may develop antibiotic-refractory Lyme arthritis, when synovitis persists for months to years after antibiotic therapy, most likely due to autoimmunity triggered by the infection [24] .
A minority of patients treated for Lyme disease will have persistent or relapsing nonspecific symptoms (such as fatigue, musculoskeletal pain, and cognitive complaints) after receiving an adequate course of antibiotic therapy. In the absence of another condition that would explain these nonspecific symptoms, such patients are classified as having post-Lyme disease syndrome (Box 1). The best estimates of the prevalence of post-Lyme 342 MARQUES disease syndrome come from studies of patients with erythema migrans who received appropriate antibiotic treatment. Approximately 10% to 20% of such patients have persistent or intermittent subjective symptoms of mildto-moderate intensity 12 months after completion of therapy ( Table 2) . The most common post-Lyme disease symptoms are fatigue, arthralgias, myalgias, headache, neck stiffness, paresthesias, sleeplessness, irritability, and difficulty with memory, word finding, and concentration [12, 13, [25] [26] [27] [28] . The appearance of post-Lyme disease symptoms seems to correlate with disseminated disease, a greater severity of illness at presentation, and delayed antibiotic therapy [12, [29] [30] [31] [32] [33] , but not with the duration of the initial antibiotic therapy [13, 23] . Children appear to be less likely to develop postLyme disease symptoms [34] [35] [36] [37] [38] [39] [40] [41] [42] .
The possible causes of post-Lyme disease symptoms
The mechanisms underlying post-Lyme disease symptoms are not known and are likely to be multifactorial. Possible explanations include persistent infection with B. burgdorferi, other tick-borne infections, part of the expected resolution of symptoms after treatment, postinfective fatigue syndrome, autoimmune mechanisms, and intercurrent conditions. In many patients, these symptoms probably represent the natural evolution of response after therapy, as the percentage of patients reporting symptoms after antibiotic treatment decreases over time. In one study of patients treated for erythema migrans, 34% had symptoms at 3 weeks, 24% at 3 months, and 17% at 12 months [13] . In other patients, a postinfective fatigue syndrome may be triggered by Lyme disease, as has been shown to occur with other infections. Prolonged fatigue after infections is relatively common, and it can be disabling and persistent. A recent study showed that postinfective fatigue syndrome could be predicted by the severity of the acute illness, and its incidence was similar after the different infections [43] . In this cohort, the case rate for provisional postinfective fatigue syndrome was 35% (87/250) at 6 weeks, 27% (67/250) at 3 months, and 9% (22/250) at 12 months [43] , rates similar to those reported in patients treated for erythema migrans [13] . The mechanisms that are triggered during the acute illness and that sustain the persistent symptoms in postinfective fatigue syndrome are currently unknown.
It also important to recognize that there is a substantial background prevalence of similar symptoms in the general population. Musculoskeletal pain is a very common complaint. For example, in a random survey of 3664 persons aged 25 years and over, stratified by age and gender, 44.4% of the individuals reported musculoskeletal pain lasting longer than 3 months, with lower back, shoulder, neck and knee being the most frequently affected sites, and 15.6% reporting chronic pain involving two to three sites. The prevalence of chronic widespread pain was 5.2% [44] . In another population-based cross-sectional survey that included 2299 subjects, 15% reported chronic widespread pain, [76] 86 patients referred to the Rheumatology Unit at the Medical University Policlinic in Bonn, Germany
Only eight patients had ongoing or recent Lyme disease. The most common diagnoses were degenerative disorders of the spine (29%), arthropathies related to psoriasis or rheumatoid arthritis (17%), and spondiloarthropathy.
Box 1. Proposed definition of post-Lyme disease syndrome
Inclusion criteria An adult or child who has a documented episode of early or late Lyme disease fulfilling the case definition of the Centers for Disease Control and Prevention; if based on erythema migrans, the diagnosis must be made and documented by an experienced health care practitioner. After treatment of the episode of Lyme disease with a generally accepted treatment regimen, there is resolution or stabilization of the objective manifestation(s) of Lyme disease. Onset of any of the following subjective symptoms within 6 months of the diagnosis of Lyme disease and persistence of continuous or relapsing symptoms for at least a 6-month period after completion of antibiotic therapy: Fatigue Widespread musculoskeletal pain Complaints of cognitive difficulties Subjective symptoms are of such severity that, when present, they result in substantial reduction in previous levels of occupational, educational, social, or personal activities.
Exclusion criteria
An active, untreated, well-documented coinfection, such as babesiosis The presence of objective abnormalities on physical examination or on neuropsychological testing that may explain the patient's complaints A diagnosis of fibromyalgia or chronic fatigue syndrome before the onset of Lyme disease A prolonged history of undiagnosed or unexplained somatic complaints, such as musculoskeletal pains or fatigue, before the onset of Lyme disease. A diagnosis of an underlying disease or condition that might explain the patient's symptoms Laboratory or imaging abnormalities that might suggest an undiagnosed process distinct from post-Lyme disease syndrome Although testing by either culture or polymerase chain reaction for evidence of Borrelia burgdorferi infection is not required, should such testing be done by reliable methods, a positive result would be an exclusion. and 8% reported chronic fatigue [45] . Insomnia is also common, and can be associated with anxiety, depression, and pain [46] . Musculoskeletal pain, fatigue, and sleep disturbance often are reported together [47] .
Recent studies showed little evidence of a substantial role of other tickborne infections in most patients who had post-Lyme disease syndrome [4, [48] [49] [50] . There has been little research in the role of autoimmunity in post-Lyme disease syndrome, but one study showed no association between a class 2 allele or genotype [51] .
A major concern has been that the symptoms of post-Lyme disease syndrome may represent persistent infection with B. burgdorferi. A review of the earliest studies of patients who had Lyme disease demonstrates the uncertainty that surrounded the disease and explains in part some of the confusion regarding chronic Lyme disease. During those initial years, nonspecific symptoms were classified as part of minor late manifestations or complications of Lyme disease, to differentiate from the major manifestations, which included arthritis, meningoencephalitis, and carditis [25, [29] [30] [31] . In some cases, facial palsy and brief episodes of arthritis were grouped together with nonspecific symptoms as part of minor manifestations of late Lyme disease [29, 30] , and, in some studies, all patients were grouped together [29, 31] . Although arthritis, meningoencephalitis, carditis and other objective manifestations of Lyme disease are clear evidence of treatment failure and require antibiotic therapy [14] , there was uncertainty about whether nonspecific minor symptoms also could represent treatment failures and whether longer courses of antibiotics or different antibiotic regimens may be needed in some of the patients [30, 31, 52, 53] .
As the studies progressed, and antibiotic therapy for Lyme disease evolved, it became rare for patients who had erythema migrans treated with currently recommended antibiotic regimens to develop an objective manifestation of Lyme disease [13] . Physicians also gained more experience following patients who were treated with antibiotics, and, with longer periods of observation, it became apparent that these nonspecific symptoms frequently resolved without further antibiotic treatment, and that antibiotic therapy did not hasten their resolution [33, 54] . Further studies also showed that symptomatic patients were not more likely to be seropositive than patients without symptoms and that patients did not develop objective manifestations of late Lyme disease [12, 18] . Although earlier, smaller studies showed a higher prevalence of recurrent arthralgias, symptoms of memory impairment, and other symptoms in persons with a history of Lyme disease compared with controls [32, 33] , larger cohort studies showed no differences on physical examination and neurocognitive testing [55] , and no difference in the frequency of symptoms between patients who had Lyme disease and age-matched controls [39] .
Objective evidence of Borrelia infection in patients who have post-Lyme disease syndrome has not been found using polymerase chain reaction (PCR) [4, 49] or culture [4, 49] . It should be noted, however, that 347 CHRONIC LYME DISEASE: A REVIEW All children responded promptly, and 94% were asymptomatic by 4 weeks, with 5% having arthralgia, myalgia, and fatigue, and 1% had residual facial palsy. All patients recovered completely at 6 months, but for one patient who had mild recurrent arthralgia.
At 2-year follow-up, only 1 child had mild recurrent arthralgia.
[ 35] 1996 United States Randomized doubleblinded multicenter study 111 patients received azithromycin 500 mg orally once a day (with placebo orally twice a day) for 7 days (followed by placebo three times a day for 13 days) compared with 106 patients given amoxicillin 500 mg orally three times a day for 20 days.
At day 20, 84 (76%) had a complete response in the azithromycin group versus 93 (88%) in the amoxicillin group. Partial response was seen in 24 (22%) patients in the azithromycin group versus13 (12%) in the amoxicillin group. There were three failures in the azithromycin group.
At 180 days, 17 patients in the azithromycin group versus 4 patients in the amoxicillin group were considered relapses. A partial response at day 20 was predictive of relapse [53] (continued on next page) After 3 months, 84% to 92% of cases were asymptomatic.
Only 8 (10%) of the 81 cases followed for R1 year were symptomatic at their last visit, a mean of 5.6 AE 2.6 years of follow-up. Their symptoms tended to be intermittent and mild, with only three patients (4%) consistently symptomatic at each follow-up visit. Presenting with symptoms during follow up was associated with presenting with more symptoms and of greater severity, and presenting with multiple EM at the first visit.
[12]
(continued on next page) 60 patients received a single 2g dose of intravenous ceftriaxone followed by doxycycline 100 mg orally twice a day for 10 days, followed by placebo orally twice a day for 10 days. 61 patients received a single dose of intravenous placebo, followed by doxycycline 100 mg orally twice a day for 10 days, followed by placebo twice a day for 10 days. 59 patients received a single placebo injection followed by doxycycline 100 mg orally twice a day for 20 days.
The complete response rate was similar in the three groups at all time points. At 20 days, 97 patients had a complete response; 47 had a partial response, and 1 was a failure. The only failure was a patient treated with doxycycline for 10 days who developed meningitis at 18 days and was treated with ceftriaxone.
At 12 months, 103 patients had a complete response, and 24 had a partial response. At 30 months, 86 patients had a complete response, and 12 had a partial response.
[13]
B. burgdorferi culture and PCR have low sensitivity in most body fluids from patients who have Lyme disease [56, 57] . The initial report claiming frequent isolation of B. burgdorferi from patients who had post-Lyme disease syndrome using MPM media [58] has not been reproduced by other researchers [49, 59, 60] . One study reported a high percentage of B. burgdorferi PCR in urine samples of patients diagnosed with chronic Lyme disease [61] , but these results have not been validated. Other tests that have not been helpful to evaluate patients who have post-Lyme disease syndrome include changes in C6 antibody levels [62] and antibodies in immune complexes [63] .
There have been interesting reports of B. burgdorferi being present after antibiotic therapy in dogs and mice as assessed by PCR, but not by culture [64] [65] [66] . More detailed studies suggested that these organism were attenuated, noninfectious spirochetes [66] . The significance of these findings is, at present, unclear. A recent study reported that B. burgdorferi was found by culture in a few mice treated with antitumor necrosis factor (TNF) antibody either simultaneously or 4 weeks after ceftriaxone therapy [67] . The number of mice treated in this study, however, was small, and the findings need further verification.
Studies of antibiotic treatment in post-Lyme disease syndrome
There are now four randomized, placebo-controlled, double-blinded studies of antibiotic therapy in patients who had post-Lyme disease syndrome, and all showed that prolonged antibiotic therapy offers no sustained benefit and has potential serious adverse effects (Table 3 ). The first two studies, one for patients who were IgG seropositive for B burgdorferi at enrollment, and the other for seronegative patients, were published together [49] . All patients had well-documented Lyme disease and had received antibiotic therapy previously. These studies enrolled 78 seropositive patients and 51 seronegative patients. Patients were randomized to receive intravenous ceftriaxone, 2 g daily for 30 days, followed by oral doxycycline, 100 mg twice a day for 60 days, or matching intravenous and oral placebos. The primary outcome was improvement in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) score on day 180 of the study. Patients previously had received an average of three courses of antibiotic therapy and had had symptoms for a median of 4.6 years. Most patients complained of pain, fatigue, and cognitive changes. The studies were stopped early because a planned interim analysis showed that there was little chance of demonstrating a difference between treatment groups. Intentionto-treat analyses showed no significant differences between patients in the antibiotic groups and those in the placebo groups in the seropositive study, the seronegative study, or both studies combined. About one-third of the patients improved; one-third of the patients remained unchanged, and one-third of the patients worsened at each time point. There were two serious adverse events related to treatment. The third study enrolled 55 patients with post-Lyme disease syndrome who had significant fatigue [3] . These patients were randomized to ceftriaxone 2 g (28 patients) or placebo (24 patients) intravenously daily for 28 days. The primary clinical endpoints were improvement in the fatigue and mental speed at 6 months. Eighteen patients (64%) in the ceftriaxone group and 19 patients (70.4%) in the placebo group were ELISA and Western blot seropositive at enrollment, while 12 (43%) in the ceftriaxone group and 14 (52%) in the placebo group had received at least 2 weeks of intravenous ceftriaxone before the study. The intent-to-treat analysis showed modest improvement of fatigue with ceftriaxone therapy, with similar results for patients who received therapy and completed follow up. There was no improvement in mental speed or other neurocognitive measures. Three patients in each group discontinued therapy because of adverse effects, and four had to be hospitalized. In this study, significantly more patients who received ceftriaxone were able to correctly guess their assignment compared with placebo recipients.
The fourth study enrolled patients with post-Lyme disease syndrome who were seropositive by IgG Western blot, had objective memory impairment, and had received at least 3 weeks of intravenous antibiotic therapy [4] . There were only 37 patients enrolled, and they were randomized 2:1 to receive 10 weeks of intravenous ceftriaxone (23 patients) or intravenous placebo (14 patients). The primary outcome was improvement in memory performance at 12 weeks. Patients were evaluated at 24 weeks for durability of benefit. Twenty patients in the ceftriaxone group and 12 patients in the placebo group completed the follow-up. In comparisons using a model with an aggregate of the six domains of neurocognitive performance measured in the study, the ceftriaxone group showed a slightly greater improvement at 12 weeks. At 24 weeks, both groups had improved similarly from baseline. Exploratory analysis suggested a greater improvement in physical functioning and pain among patients, with greater baseline impairment treated with ceftriaxone. There were nine patients who discontinued therapy because of adverse effects, and in seven patients, these effects were related to the treatment.
Three of these randomized trials have been criticized as offering too little, too late [68] [69] [70] , based on retrospective, open-label case-series that suggested a possible role of prolonged antibiotic therapy in patients diagnosed with chronic Lyme disease [71, 72] . In general, case series studies are fraught with potential for biases. For example, both patients and physicians' choices will affect the decision to prescribe a drug to a particular patient. The lack of blinding can affect outcomes, especially for subjective measures. Without a comparison group, it is not possible to know if an outcome is related to an intervention, or to a placebo effect, time, or chance. Case series and case reports are classified at the lowest level of strength in the hierarchy of evidence-based medicine [73] . They are best used for hypothesis generation to be investigated by stronger study designs.
MARQUES

Summary
At this point, the overwhelming evidence shows that prolonged antibiotic therapy, as tested in the clinical trials, does not offer lasting or substantive benefit in treating patients who have post-Lyme disease syndrome. Therefore, it is time to move forward to test other approaches that may help these patients. Unfortunately, no prospective studies of other treatment modalities for patients who have post-Lyme disease syndrome have been performed. Because of the significant placebo effect and the variation in symptom intensity seem in these patients, interventional studies should have a randomized controlled design, with clearly defined target patient populations. For the health care provider taking care of these patients, as always, one should review carefully the evidence for the diagnosis of Lyme disease and not lose sight that these patients can develop other unrelated conditions. It is important that patients be offered the best advice based on current, evidence-based information [74] . Most importantly, there should be a collaborative approach to the treatment process with the patient. Hopefully, further research to understand chronic Lyme disease and the reasons underlying persistent symptoms after Lyme disease will lead to the development of beneficial therapies.
